

Supporting Information

Gold-catalyzed [5+2] cycloaddition of quinolinium zwitterions and allenamides as an efficient route to fused 1,4-diazepines

Nirupam De^a, Choong Eui Song,^c Do Hyun Ryu,^c and Eun Jeong Yoo^{*a,b}

^aDepartment of Applied Chemistry, Kyung Hee University, Yongin, 17104, Korea

^bGlobal Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin, 17104, Korea

^cDepartment of Chemistry, Sungkyunkwan University, Suwon, 16419, Korea

E-mail: ejyoo@khu.ac.kr

Table of contents

I	General information	S-2
II	Experimental Procedures	S-2
II-1	General experimental procedure for the synthesis of quinolinium zwitterions	
II-2	General experimental procedure for the optimization studies for [5+2] cycloaddition reactions (Table 1)	
II-3	General procedure for the [5+2] cycloadditions of quinolinium zwitterions (1) and allenamides (2) (Table 2, Table 3)	
II-4	Experimental procedure for selective reduction of cycloadduct 3aa	
II-5	Experimental procedure for Suzuki coupling reaction of cycloadduct 3ea	
III	Spectroscopic data	S-4
V	References	S-20
VI	Copies of Spectral Data of Compounds Obtained in this Study	S-21
VII	Stereochemistry assignment	S-81

Acknowledgment We acknowledge the Korea Basic Science Institute (KBSI) for the HRMS.

I. General Information

Unless otherwise stated, all commercial reagents and solvents were used without additional purification. Allenamides were prepared following literature reported procedures by base catalyzed isomerization of the corresponding propargyl precursors.^{S1} Analytical data are in agreement with the literature. Analytical thin layer chromatography (TLC) was performed on Merck pre-coated silica gel 60 F254 plates. Visualization on TLC was achieved by use of UV light (254 nm). Flash column chromatography was undertaken on silica gel (Merck Kiesel gel 60 F254 400-630 mesh). ¹H NMR was recorded on Bruker DPX FT (400 MHz). Chemical shifts were quoted in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following abbreviations were used to describe peak splitting patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Coupling constants, J, were reported in hertz unit (Hz). ¹³C NMR was recorded on Bruker FT AM 400 (100 MHz) and was fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm either in referenced to the center line of a triplet at 77.0 ppm of chloroform-d or in referenced to the center line of a septet at 39.5 ppm of dimethylsulfoxide-d₆. Infrared spectra were recorded on a Nicolet 6700 FT/IR spectrometer (Thermo Electron Corporation, WI, USA). Frequencies are given in reciprocal centimeters (cm⁻¹) and only selected absorbance is reported. High resolution mass spectra were obtained from the Korea Basic Science Institute (Daegu) by EI/FAB method.

II. Experimental Procedures


II-1. General experimental procedure for the synthesis of quinolinium zwitterions:

To a test tube with a triangular-shaped stir bar were added 4-phenyl-1-toluenesulfonyl-1,2,3-triazole (2.0 equiv), and Rh₂(OPiv)₄ (4.0 mol %), and *p*-xylene (2.0 mL) under N₂ atmosphere. To this stirred reaction mixture was added respective quinoline derivative (0.2 mmol) and the reaction mixture was stirred at 110 °C (TLC). The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove the solvent and the residue was purified by chromatography on silica gel to give the desired product **1a-v**.

II-2. General experimental procedure for the optimization studies for [5+2] cycloaddition reactions (Table 1): To a flame dried test tube with a triangular-shaped stir bar were added quinolinium zwitterion (**1a**, 0.1 mmol), allenamide (**2a**, 1.3 equiv), catalyst and solvent (2.0 mL). The reaction mixture was stirred at indicated temperature and monitored by TLC. Reaction mixture was then cooled to room temperature, filtered through a pad of celite and then washed with CH₂Cl₂ (5 mL x 3). The combined filtrates were concentrated under reduced pressure. The NMR yield of desired product **3aa** was determined by integration using CH₂Br₂ as internal standard.

■ **Gold(I)-Catalyzed cycloaddition between pyridinium zwitterion and allenamide (Scheme S1)**


A similar reaction profile using pyridinium zwitterion (**1a'**) and allenamide **2j** formed a cascade [5+2]/[2+2]-cycloadduct in low yield (Eq. 1, Scheme S1) following a similar sequence as observed for the reaction between pyridinium zwitterion (**1a'**) and benzyne (Eq. 2).^{S2}



Scheme S1. Cascade [5+2]/[2+2] cycloaddition of pyridinium zwitterion and allenamide

■ **Intramolecular cyclization of quinolinium zwitterion at high temperature (Scheme S2)**

During optimization studies, a control experiment under catalyst-free conditions (Table 1, entry 11) afforded an intramolecular cyclized product (**4**) under refluxing condition (Scheme S2).



Scheme S2. Thermal cyclization of quinolinium zwitterion under catalyst-free condition

II-3. General procedure for the [5+2] cycloadditions of quinolinium zwitterions (1) and allenamides (2) (Table 2, Table 3):

To a flame dried test tube with a triangular-shaped stir bar were added quinolinium zwitterion (**1**, 0.1 mmol), allenamides (**2**, 1.3 equiv), AuCl (5 mol%) and THF (2.0 mL). The reaction mixture was stirred at room temperature and monitored by TLC. After completion, the reaction mixture was filtered through a pad of celite and then washed with CH₂Cl₂ (5 mL x 3). The combined filtrates were concentrated under reduced pressure. The organic residue was purified by chromatography on silica gel to give the desired product **3** (eluent; EtOAc:Hexane = 1:4).

II-4. Experimental procedure for selective reduction of cycloadduct 3aa:


To a flame dried two-neck round bottom flask, equipped with a stir bar, were added cycloadduct **3aa** (0.2 mmol), Pd/C (20 mol%) and EtOAc (10 mL). The reaction vessel was closed, evacuated three times and backfilled by H₂-balloon. The reaction mixture was stirred at room temperature under H₂-balloon pressure for 8 h (TLC). After completion, the reaction mixture was filtered through a pad of celite, washed with EtOAc (5 mL x 3). The combined filtrates were concentrated under reduced pressure and the resulting residue was purified by chromatography on silica gel (eluent; EtOAc:Hexane = 1:4) to afford the desired product **4aa** (96%).

II-5. Experimental procedure for Suzuki coupling reaction of cycloadduct 3ea:

To a flame dried test tube with a triangular-shaped stir bar were added cycloadduct **3ea** (0.1 mmol), Phenylboronic acid (1.5 equiv) in 1,4-dioxane (5 mL). To this stirred solution was added K₂CO₃ (2.5 equiv, dissolved in 1.0 mL H₂O). The reaction mixture was then degassed (N₂) for 10 minutes prior to addition of Pd(PPh₃)₄ (5 mol%) and the reaction mixture was heated for 6 h at 100 °C. Reaction mixture was then cooled to room temperature, filtered through a pad of celite and concentrated in vacuo. The crude mixture was purified by silica gel column chromatography to afford compound **5ea** (56%).


III. Spectroscopic data

2-nitro-*N*-phenyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide:




Yellow viscous oil; ¹H NMR (400 MHz, CDCl₃) δ 7.70-7.62 (m, 3H), 7.53-7.49 (m, 1H), 7.36-7.33 (m, 3H), 7.30-7.28 (m, 2H), 4.59 (d, *J* = 2.4 Hz, 2H), 2.26 (t, *J* = 2.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 148.0, 137.7, 133.9, 132.2, 132.0, 131.3, 129.6, 129.4, 129.0, 124.1, 78.2, 73.8, 42.4; IR (KBr) ν 3292, 3098, 2978, 2123, 1655, 1593, 1484, 1373, 1171 cm⁻¹; HRMS (FAB) *m/z* calcd. for C₁₅H₁₂N₂O₄S [M+H]⁺: 317.0591, found: 317.0593.

(2-nitro-*N*-phenyl-*N*-(propa-1,2-dien-1-yl)benzenesulfonamide (2h):



Light yellow viscous oil; ¹H NMR (400 MHz, CDCl₃) δ 7.71-7.64 (m, 2H), 7.62-7.60 (m, 1H), 7.54-7.50 (m, 1H), 7.35-7.29 (m, 3H), 7.21-7.14 (m, 3H), 5.09 (d, *J* = 6.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 200.4, 148.1, 136.1, 134.1, 131.9, 131.5, 131.3, 130.0, 129.2, 129.1, 124.1, 103.1, 88.2; IR (KBr) ν 3098, 3067, 2905, 1965, 1543, 1373, 1252, 1171, 1063 cm⁻¹; HRMS (FAB) *m/z* calcd. for C₁₅H₁₂N₂O₄S [M+H]⁺: 317.0591, found: 317.0598.


(*Z*)-(2-Phenyl-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1a):



Purple solid; m.p. 207.4-208.6 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.41-9.34 (m, 2H), 8.53 (d, *J* = 7.1 Hz, 1H), 8.28-8.24 (m, 1H), 8.09 (s, 1H), 8.01-7.94 (m, 3H), 7.41 (d, *J* = 7.7 Hz, 2H), 7.19-7.17 (m, 4H), 7.03-7.00 (m, 1H), 6.81 (d, *J* = 7.5 Hz, 2H), 2.32 (s, 3H);


^{13}C NMR (100 MHz, DMSO d_6) δ 153.6, 147.7, 139.3, 135.7, 130.4, 130.2, 129.9, 129.0, 128.7, 125.3, 124.1, 123.0, 119.8, 119.7, 20.8; IR (KBr) ν 3054.7, 2986.2, 1591.9, 1421.3, 1264.1, 1130.1, 1082.8, 964.2 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{S}_2\text{O}$ $[\text{M}+\text{H}]^+$: 401.1324, found: 401.1322.

(Z)-(2-(6-methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1b):




Purple solid; m.p. 214.2-215.9°C; ^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, J = 8.4 Hz, 1H), 8.64 (dd, J = 5.8 Hz, 1.4 Hz, 1H), 8.27 (s, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.83 (s, 1H), 7.76 (dd, J = 8.6 Hz, 5.8 Hz, 1H), 7.65 (d, J = 8.24 Hz, 2H), 7.56 (dd, J = 9.02 Hz, 1.76 Hz, 1H), 7.15-7.11 (m, 4H), 7.00 (t, J = 7.32 Hz, 1H), 6.72 (dd, J = 8.68 Hz, 1.2 Hz, 2H), 2.49 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.9, 145.8, 143.3, 140.8, 140.6, 140.1, 138.9, 137.5, 136.8, 130.7, 129.0, 128.8, 128.4, 126.0, 124.5, 122.0, 120.8, 120.2, 114.2, 21.4, 21.3; IR (KBr) ν 3054, 2984, 1589, 1516, 1444, 1246, 1130, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 415.1475, found: 415.1477.

(Z)-(2-(6-Methoxyquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1c):




Red solid; m.p. 195.4-196.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.78 (d, J = 8.4 Hz, 1H), 8.47 (dd, J = 5.6, 1.3 Hz, 1H), 8.28 (s, 1H), 7.91 (d, J = 9.2 Hz, 1H), 7.69 (d, J = 8.2 Hz, 2H), 7.60 (dd, J = 8.4, 5.6 Hz, 1H), 7.36-7.32 (m, 2H), 7.18-7.12 (m, 4H), 7.00 (t, J = 7.2 Hz, 1H), 6.73-6.70 (m, 2H), 3.83 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.7, 148.0, 145.4, 143.2, 140.3, 140.3, 136.6, 135.9, 132.4, 129.0, 128.4, 125.9, 124.6, 122.1, 121.9, 120.2, 114.4, 107.1, 56.2, 21.3; IR (KBr) ν 3055, 2978, 1591, 1514, 1394, 1266, 1127, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 431.1424, found: 431.1431.

(Z)-(2-(6-(methoxycarbonyl)quinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1d):




Purple solid; m.p. 122.6-124.1°C; ^1H NMR (400 MHz, CDCl_3) δ 9.03 (d, J = 8.2 Hz, 1H), 8.86 (d, J = 5.5 Hz, 1H), 8.72 (s, 1H), 8.26 (s, 1H), 8.24 (dd, J = 9.2 Hz, 1.6 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.95 (dd, J = 8.2 Hz, 5.6 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.17-7.13 (m, 4H), 7.02 (t, J = 7.2 Hz, 1H), 6.73 (d, J = 7.4 Hz, 2H), 4.00 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 153.9, 148.3, 142.8, 141.8, 140.5, 136.3, 134.5, 132.1, 131.1, 129.7, 129.5, 129.1, 129.0, 125.9, 124.9, 123.4, 121.4, 120.4, 114.4, 53.0, 21.3; IR (KBr) ν 3064, 2950, 1724, 1594, 1516, 1442, 1275, 1134, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$: 459.1374, found: 459.1380.

(Z)-(2-(6-bromoquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1e):




Brown solid; m.p. 155.3-157.0°C; ^1H NMR (400 MHz, CDCl_3) δ 8.93 (d, J = 8.4 Hz, 1H), 8.47 (dd, J = 5.6 Hz, 1.2 Hz, 1H), 8.27 (s, 1H), 8.24 (d, J = 2.0 Hz, 1H), 7.88 (d, J = 9.4 Hz, 1H), 7.80-7.73 (m, 2H), 7.67 (d, J = 8.2 Hz, 2H), 7.18-7.13 (m, 4H), 7.03 (t, J = 7.2 Hz, 1H), 6.73-6.70 (m, 2H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.0, 146.3, 143.0, 140.6, 140.5, 138.7, 138.5, 136.3, 131.9, 131.2, 129.1, 125.9, 124.8, 124.2, 123.2, 122.3, 120.2, 114.1, 21.3; IR (KBr) ν 3059, 2919, 1590, 1504, 1445, 1244, 1130, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 479.0424, found: 479.0430.

(Z)-(2-(6-chloroquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1f):




Purple solid; m.p. 149.9-151.6°C; ^1H NMR (400 MHz, CDCl_3) δ 8.91 (d, J = 8.0 Hz, 1H), 8.76-8.74 (m, 1H), 8.27 (s, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.83-7.80 (m, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.62 (dd, J = 9.2 Hz, J = 2.2 Hz, 1H), 7.18-7.14 (m, 4H), 7.03 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 7.4 Hz, 2H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.0, 146.4, 143.0, 140.6, 140.5, 138.6, 136.4, 136.1, 136.0, 131.0, 129.14, 129.09, 128.5, 125.9, 124.9, 123.3, 122.5, 120.3, 114.2, 21.4; IR (KBr) ν 3060, 2918, 1589, 1510, 1445, 1244, 1129, 1086 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 435.0929, found: 435.0937.

(Z)-(2-(7-Methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1g):




Violet solid; m.p. 204.3-205.1 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.86 (d, J = 8.0 Hz, 1H), 8.61 (dd, J = 5.8, 1.6 Hz, 1H), 8.29 (s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 7.70 (dd, J = 8.0, 5.8 Hz, 1H), 7.64 (d, J = 7.8 Hz, 2H), 7.55 (dd, J = 8.4, 1.2 Hz, 1H), 7.16-7.12 (m, 4H), 7.00 (t, J = 7.2 Hz, 1H), 6.72 (d, J = 7.8 Hz, 2H), 2.41 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.5, 147.9, 146.2, 143.4, 140.7, 140.1, 136.8, 132.2, 129.6, 129.0, 128.90, 128.87, 125.9, 124.5, 121.1, 120.2, 119.7, 114.0, 21.7, 21.3; IR (KBr) ν 3060, 2920, 1590, 1510, 1443, 1245, 1130, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 415.1475, found: 415.1479.

(Z)-(2-(5-bromoquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1h):




Purple solid; m.p. 156.5-158.1°C; ^1H NMR (400 MHz, CDCl_3) δ 9.22 (d, J = 8.2 Hz, 1H), 8.87 (d, J = 4.4 Hz, 1H), 8.27 (s, 1H), 8.07-8.04 (m, 3H), 7.63-7.58 (m, 3H), 7.17-7.11 (m, 4H), 7.02 (t, J = 7.2 Hz, 1H), 6.72 (d, J = 7.8 Hz, 2H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.4, 145.7, 142.8, 141.4, 140.6, 140.3, 136.5, 135.3, 133.9, 129.7, 129.0, 128.9, 126.0, 124.8, 124.0, 123.6, 120.9, 120.3, 114.3, 21.3; IR (KBr) ν 3069, 2921, 1591, 1515, 1444, 1246, 1132, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 479.0424, found: 479.0431.

(Z)-(2-(5-chloroquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1i):



Blue solid; m.p. 141.1-142.8°C; ^1H NMR (400 MHz, CDCl_3) δ 9.25 (d, J = 8.4 Hz, 1H), 8.89 (d, J = 5.0 Hz, 1H), 8.26 (s, 1H), 8.07-8.03 (m, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.70-7.66 (m, 1H), 7.62 (d, J = 8.2 Hz, 2H), 7.17-7.11 (m, 4H), 7.02 (t, J = 7.4 Hz, 1H), 6.72 (d, J = 8.2 Hz, 2H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.5, 143.0, 142.9, 141.3, 140.8, 140.2, 136.6, 134.9, 133.8, 130.1, 129.0, 128.8, 128.7, 126.0, 124.7, 123.3, 120.3, 114.3, 53.4, 21.3; IR (KBr) ν 3075, 2919, 1590, 1515, 1444, 1246, 1129, 1086 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 435.0929, found: 435.0931.


(Z)-(2-phenyl-2-(3-phenylquinolin-1-ium-1-yl)vinyl)(tosyl)amide (1j):



Purple solid; m.p. 156.3-157.9°C; ^1H NMR (400 MHz, CDCl_3) δ 9.09 (d, J = 1.6 Hz, 1H), 8.93 (d, J = 2.0 Hz, 1H), 8.38 (s, 1H), 8.22-8.18 (m, 1H), 7.97-7.95 (m, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.65-7.50 (m, 2H), 7.47-7.37 (m, 5H), 7.17-7.14 (m, 4H), 7.02 (t, J = 7.4 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.0, 143.3, 142.8, 141.0, 140.1, 138.6, 136.6, 135.0, 134.7, 132.9, 130.6, 130.4, 129.9, 129.8, 129.5, 129.0, 128.9,


127.1, 126.0, 124.6, 120.5, 120.3, 114.9, 21.4; IR (KBr) ν 3055, 2920, 1591, 1516, 1447, 1343, 1244, 1134, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{30}\text{H}_{24}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 477.1632, found: 477.1639..

(Z)-(2-(3-methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1k):




Brown solid; m.p. 204.2-206.0°C; ^1H NMR (400 MHz, CDCl_3) δ 8.74 (s, 1H), 8.58 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 8.08-8.06 (m, 1H), 7.98-7.96 (m, 1H), 7.70-7.65 (m, 4H), 7.16-7.12 (m, 4H), 7.00 (t, J = 7.4 Hz, 1H), 6.72 (dd, J = 8.4 Hz, 1.2 Hz, 2H), 2.46 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.9, 145.5, 143.3, 141.1, 140.0, 138.9, 136.9, 134.4, 132.6, 130.4, 129.9, 129.0, 128.8, 126.0, 124.5, 121.0, 120.2, 114.1, 53.4, 21.3, 18.5; IR (KBr) ν 3043, 2920, 1585, 1513, 1445, 1243, 1130, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 415.1475, found: 415.1483.

(Z)-(2-(quinolin-1-ium-1-yl)-2-(p-tolyl)vinyl)(tosyl)amide (1l):




Grey solid; m.p. 165.9-168.1 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.93 (d, J = 8.2 Hz, 1H), 8.68 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.78-7.64 (m, 5H), 7.14 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 8.0 Hz, 2H), 6.63 (d, J = 8.2 Hz, 2H), 2.35 (s, 3H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.0, 146.8, 143.3, 140.1, 139.8, 135.2, 134.5, 133.9, 130.4, 130.0, 129.7, 129.6, 128.9, 125.9, 122.0, 120.9, 120.4, 114.6, 21.3, 20.8; IR (KBr) ν 3023, 2981, 2860, 1600, 1518, 1382 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 415.1480, found: 415.1478.

(Z)-(2-(4-Bromophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1m):




Brown solid; m.p. 185.6-186.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.93 (d, J = 8.2 Hz, 1H), 8.76 (d, J = 4.7 Hz, 1H), 8.28 (s, 1H), 8.15 (d, J = 9.2 Hz, 1H), 8.0 (d, J = 8.2 Hz, 1H), 7.87-7.76 (m, 3H), 7.26 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.58 (d, J = 8.7 Hz, 2H), 2.56 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.4, 146.7, 142.9, 141.6, 140.3, 140.2, 135.8, 135.6, 132.0, 130.5, 130.0, 130.0, 128.9, 125.9, 122.2, 121.6, 120.9, 117.5, 113.0, 21.3; IR (KBr) ν 3060, 2978, 1592, 1580, 1518, 1399, 1240, 1129, 1080 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 479.0423, found: 479.0427.

(Z)-(2-(3-Fluorophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1n):



Red solid; m.p. 220.1-222.7 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.39 (d, J = 8.3 Hz, 1H), 9.34 (d, J = 5.4 Hz, 1H), 8.53-8.51 (m, 1H), 8.27-8.24 (m, 1H), 8.16 (s, 1H), 8.04-7.92 (m, 3H), 7.42 (d, J = 7.4 Hz, 2H), 7.23-7.17 (m, 3H), 6.82-6.78 (m, 1H), 6.65-6.61 (m, 2H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 164.1, 161.7, 153.7, 147.9, 143.4, 141.4, 139.7, 139.2, 135.8, 130.9, 130.8, 130.4, 130.2, 129.9, 128.8, 125.3, 123.1, 119.5, 115.7, 112.3, 110.3, 110.1, 106.4, 106.1, 20.8; IR (KBr) ν 3069, 2979, 2921, 1594, 1513, 1437, 1245, 1130, 1086 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{19}\text{FN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 419.1225, found: 419.1233.


(Z)-(2-(3-Fluorophenyl)-2-(6-methoxyquinolin-1-ium-1-yl)vinyl)(tosyl)amide (1o):



Violet solid; m.p. 208.1-208.9 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.77 (d, J = 8.3 Hz, 1H), 8.49 (d, J = 4.5 Hz, 1H), 8.32 (s, 1H), 7.89 (d, J = 9.3 Hz, 1H), 7.67 (d, J = 8.2 Hz,


3H), 7.39-7.35 (m, 2H), 7.17 (d, $J = 8.0$ Hz, 2H), 7.12-7.07 (m, 1H), 6.67 (td, $J = 1.9, 8.3$ Hz, 1H), 6.52 (d, $J = 8.0$ Hz, 1H), 6.31 (d, $J = 10.9$ Hz, 1H), 3.85 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.7, 162.2, 159.9, 148.3, 145.3, 142.9, 141.8, 140.5, 139.1, 139.0, 136.0, 132.4, 130.6, 130.5, 129.0, 128.7, 126.0, 122.2, 122.0, 115.5, 113.1, 111.1, 110.8, 107.0, 106.8, 106.6, 56.2, 21.3; IR (KBr) ν 3062, 2979, 1586, 1519, 1437, 1396, 1259, 1128, 1082 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{21}\text{FN}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 449.1330, found: 449.1334.

(Z)-(2-(quinolin-1-ium-1-yl)-2-(3-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1p):




Red solid; m.p. 201.7-203.3 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.96 (d, $J = 8.4$ Hz, 1H), 8.77 (dd, $J = 5.8$ Hz, 1.4 Hz, 1H), 8.40 (s, 1H), 8.18-8.16 (m, 1H), 8.02-8.00 (m, 1H), 7.88 (dd, $J = 8.4$ Hz, 5.8 Hz, 1H), 7.84-7.77 (m, 2H), 7.61 (d, $J = 8.2$ Hz, 2H), 7.24-7.21 (m, 2H), 7.14 (d, $J = 8.0$ Hz, 2H), 6.93 (s, 1H), 6.86-8.83 (m, 1H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.3, 147.2, 142.8, 142.4, 140.5, 140.0, 137.5, 135.7, 131.9, 131.6, 131.3, 130.9, 130.5, 130.1, 130.0, 129.5, 128.9, 125.9, 125.2, 122.9, 122.3, 120.6, 120.5, 116.1, 112.6, 21.3; IR (KBr) ν 3074, 2979, 1586, 1514, 1347, 1263, 1129, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 469.1193, found: 469.1198.

(Z)-(2-(Quinolin-1-ium-1-yl)-2-(4-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1q):




Brown solid; m.p. 207.6-208.2 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.95 (d, $J = 8.4$ Hz, 1H), 8.78-8.76 (m, 1H), 8.45 (s, 1H), 8.18-8.16 (m, 1H), 8.00 (d, $J = 7.8$ Hz, 1H), 7.89 (dd, $J = 8.2, 5.8$ Hz, 1H), 7.84-7.78 (m, 2H), 7.61 (d, $J = 8.2$ Hz, 2H), 7.35 (d, $J = 8.4$ Hz, 2H), 7.14 (d, $J = 8.2$ Hz, 2H), 6.76 (d, $J = 8.4$ Hz, 2H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.4, 147.0, 143.2, 142.6, 140.6, 140.1, 135.7, 130.5, 130.1, 129.0, 126.01, 125.98, 125.9, 125.8, 125.54, 125.47, 122.9, 122.4, 120.6, 119.4, 112.6, 21.3; IR (KBr) ν 3075, 2925, 1586, 1323, 1245, 1139, 1112, 1084, 1063 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{25}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 469.1193, found: 469.1202.

(Z)-(2-(7-Methylquinolin-1-ium-1-yl)-2-(4-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1r):



Red solid; m.p. 213.5-214.1 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.87 (d, $J = 8.4$ Hz, 1H), 8.67-8.65 (m, 1H), 8.46 (s, 1H), 8.06 (d, $J = 8.4$ Hz, 1H), 7.82-7.78 (m, 1H), 7.75 (s, 1H), 7.64-7.60 (m, 3H), 7.36 (d, $J = 8.4$ Hz, 2H), 7.13 (d, $J = 8.0$ Hz, 2H), 6.76 (d, $J = 8.4$ Hz, 2H), 2.44 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.7, 148.4, 146.3, 143.3, 142.8, 140.7, 140.4, 140.3, 132.5, 129.6, 129.0, 128.9, 126.05, 126.01, 125.9, 125.7, 125.3, 122.9, 121.3, 119.5, 119.3, 112.4, 22.7, 21.3; IR (KBr) ν 3064, 2925, 1585, 1324, 1250, 1134, 1115, 1084, 1062 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{26}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 483.1349, found: 483.1352.


(Z)-(2-(3,5-Difluorophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1s):



Red solid; m.p. 231.2-233.2 $^{\circ}\text{C}$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.39 (d, $J = 8.2$ Hz, 1H), 9.31 (dd, $J = 5.8, 1.4$ Hz, 1H), 8.53-8.50 (m, 1H), 8.26-8.23 (m, 2H), 8.05-7.97 (m, 2H), 7.94-7.92 (m, 1H), 7.41 (d, $J = 8.4$ Hz, 2H), 7.17 (d, $J = 8.0$ Hz, 2H), 6.80-6.74 (m, 1H), 6.54-6.51 (m, 2H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 164.4, 164.3, 162.0, 161.8, 153.8, 148.1, 143.1, 143.0, 140.7, 139.8, 139.3, 135.8, 130.5,


130.3, 129.9, 128.8, 125.3, 123.2, 119.4, 111.5, 102.4, 102.2, 102.1, 98.5, 98.2, 20.8; IR (KBr) ν 3085, 2976, 1585, 1448, 1265, 1128, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{18}\text{F}_2\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 437.1130, found: 437.1137.

(Z)-(2-(3,5-bis(trifluoromethyl)phenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1t):




Red solid; m.p. 212.3-213.9°C; ^1H NMR (400 MHz, CDCl_3) δ 8.99 (d, J = 8.4 Hz, 1H), 8.81 (dd, J = 5.8 Hz, 1.6 Hz, 1H), 8.53 (s, 1H), 8.22 (dd, J = 6.2 Hz, 3.4 Hz, 1H), 8.00-7.94 (m, 2H), 7.89-7.85 (m, 2H), 7.59 (d, J = 8.2 Hz, 2H), 7.42 (s, 1H), 7.13 (d, J = 8.0 Hz, 2H), 7.06-7.03 (m, 2H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.6, 147.4, 144.3, 142.3, 140.8, 140.0, 138.9, 136.1, 134.6, 132.9, 132.5, 132.2, 131.9, 130.6, 129.0, 128.9, 127.2, 125.9, 124.4, 122.5, 121.7, 120.2, 118.6, 116.8, 111.1, 21.3; IR (KBr) ν 3084, 3030, 2926, 1574, 1392, 1276, 1133, 1084 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{26}\text{H}_{18}\text{F}_6\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 537.1066, found: 537.1068.

(Z)-(2-Phenyl-2-(quinolin-1-ium-1-yl)vinyl)((4-(trifluoromethyl)phenyl)sulfonyl)amide (1u):




Red solid; m.p. 218.2-219.5°C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.40 (d, J = 8.4 Hz, 1H), 9.36 (dd, J = 5.8 Hz, 1.4 Hz, 1H), 8.52-8.50 (m, 1H), 8.26 (dd, J = 8.4 Hz, 5.6 Hz, 1H), 8.08 (s, 1H), 7.98-7.91 (m, 3H), 7.75-7.70 (m, 4H), 7.20 (t, J = 8.0 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1H), 6.86 (d, J = 8.8 Hz, 2H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 153.4, 150.3, 147.9, 139.2, 139.0, 136.3, 135.7, 130.4, 130.1, 130.0, 129.6, 129.0, 126.0, 125.6, 125.5, 124.6, 123.1, 120.2, 119.6, 114.7, 54.9; IR (KBr) ν 3070, 3023, 1598, 1513, 1326, 1269, 1127, 1085 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{24}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 455.1036, found: 455.1039.

(Z)-(2-Phenyl-2-(quinolin-1-ium-1-yl)vinyl)(phenylsulfonyl)amide (1v):




Brown solid; m.p. 206.6-207.1°C; ^1H NMR (400 MHz, CDCl_3) δ 8.90 (d, J = 8.3 Hz, 1H), 8.77 (d, J = 5.2 Hz, 1H), 8.27 (s, 1H), 8.16-8.13 (m, 1H), 8.04-8.02 (m, 1H), 7.87-7.84 (m, 1H), 7.80-7.73 (m, 4H), 7.39-7.31 (m, 3H), 7.18-7.14 (m, 2H), 7.05-7.01 (m, 1H), 6.75 (d, J = 7.6 Hz, 2H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 153.5, 147.7, 139.2, 136.5, 135.7, 130.4, 130.1, 129.9, 129.0, 128.3, 127.8, 126.9, 126.6, 125.2, 124.3, 123.0, 120.0, 119.7, 113.7; IR (KBr) ν 3059, 2985, 1593, 1518, 1445, 1244, 1133, 1086 cm^{-1} ; HRMS (FAB) m/z calcd. for $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 387.1162, found: 387.1169.

(E)-4-methyl-N-phenyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7- σ]quinolin-5(*5aH*)-ylidene)methyl)benzenesulfonamide (3aa):




Off-white solid (96%); m.p. 177.8-179.5°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.24 (m, 2H), 7.19-7.15 (m, 7H), 7.09-7.07 (m, 3H), 6.93-6.91 (m, 3H), 6.70 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.54 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.42 (td, J = 7.4 Hz, 1.2 Hz, 1H), 6.25 (d, J = 9.6 Hz, 1H), 6.22 (d, J = 1.8 Hz, 1H), 5.84 (d, J = 8.0 Hz, 1H), 5.74 (dd, J = 9.6 Hz, 5.2 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.41-4.32 (m, 2H), 2.42 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.3, 144.1, 142.1, 139.6, 135.6, 135.1, 134.5, 133.8, 129.9, 129.6, 129.0, 128.7, 128.6, 127.8, 127.7, 127.52, 127.5, 126.9, 126.8, 126.7, 125.6, 125.3, 124.9, 122.6, 121.6, 120.7, 117.8, 113.3, 59.3, 50.4, 21.6, 21.5; IR (KBr) ν 3064, 2925, 1637, 1594, 1490, 1450, 1350, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{35}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 685.2069, found: 685.2072.

(E)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-N-(p-tolyl)benzenesulfonamide (3ab):




Light yellow solid (89%); m.p. 135.6-137.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.24 (m, 2H), 7.17-7.15 (m, 7H), 6.97 (s, 1H), 6.84-6.82 (m, 2H), 6.79-6.77 (m, 2H), 6.69 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.52-6.47 (m, 1H), 6.42-6.38 (m, 1H), 6.25-6.23 (m, 2H), 5.77 (d, J = 8.0 Hz, 1H), 5.65 (dd, J = 9.6 Hz, 5.0 Hz, 1H), 4.82-4.80 (m, 1H) 4.36 (s, 2H), 2.43 (s, 3H), 2.36 (s, 3H), 2.15 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 144.1, 142.4, 137.7, 136.7, 135.6, 135.1, 134.0, 132.6, 129.9, 129.8, 129.6, 128.9, 128.6, 127.9, 127.6, 127.4, 126.93, 126.9, 126.8, 126.0, 125.3, 124.8, 123.1, 121.6, 120.1, 117.5, 112.7, 59.1, 50.2, 21.6, 21.56, 21.0; IR (KBr) ν 3057, 3028, 2920, 1638, 1600, 1490, 1347, 1164 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 699.2225, found: 699.2229.

(E)-N-(4-methoxyphenyl)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ac):




Off-white solid (83%); m.p. 136.5-138.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.24 (m, 2H), 7.17-7.15 (m, 7H), 6.96 (s, 1H), 6.79 (d, J = 9.0 Hz, 2H), 6.69 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.56-6.53 (m, 2H), 6.50 (td, J = 7.6 Hz, 1.4 Hz, 1H), 6.40 (td, J = 7.4 Hz, 1.2 Hz, 1H), 6.26-6.24 (m, 2H), 5.77 (d, J = 8.0 Hz, 1H), 5.66 (dd, J = 9.8 Hz, 5.0 Hz, 1H), 4.87-4.85 (m, 1H) 4.36 (s, 2H), 3.64 (s, 3H), 2.43 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.9, 144.2, 144.1, 142.5, 135.6, 135.1, 133.9, 132.0, 131.8, 129.9, 129.7, 128.9, 128.6, 128.57, 127.9, 127.6, 127.5, 126.9, 126.8, 126.1, 125.3, 124.8, 123.2, 121.7, 120.0, 117.5, 114.3, 112.6, 59.1, 55.3, 50.2, 21.6, 21.56, IR (KBr) ν 3060, 2924, 1640, 1599, 1510, 1443, 1351, 1165 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_5\text{S}_2$ $[\text{M}]^+$: 715.2175, found: 715.2175.

(E)-N-(4-bromophenyl)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ad):




Light yellow solid (76%); m.p. 147.6-149.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.28-7.26 (m, 2H), 7.21-7.16 (m, 9H), 6.90 (s, 1H), 6.81 (d, J = 8.8 Hz, 2H), 6.70 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.55 (td, J = 7.6 Hz, 1.6 Hz, 1H), 6.44 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.25 (d, J = 9.8 Hz, 1H), 6.14 (d, J = 1.8 Hz, 1H), 5.85 (d, J = 8.0 Hz, 1H), 5.75 (dd, J = 9.8 Hz, 5.4 Hz, 1H), 4.90 (d, J = 5.2 Hz, 1H) 4.41-4.30 (m, 2H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.6, 144.2, 142.0, 138.9, 135.8, 135.5, 134.9, 133.5, 132.2, 130.0, 129.8, 128.8, 128.7, 128.1, 128.0, 127.8, 127.2, 127.0, 126.8, 125.6, 125.1, 124.9, 122.4, 121.4, 121.3, 120.7, 118.0, 113.5, 59.3, 50.3, 21.64, 21.58, IR (KBr) ν 3060, 2924, 1639, 1599, 1491, 1348, 1267, 1168 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{BrN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 763.1174, found: 763.1173.

(E)-N-(3-fluorophenyl)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ae):




Light yellow solid (85%); m.p. 179.7-180.8°C; ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.28-7.25 (m, 2H), 7.22-7.17 (m, 7H), 7.07-7.00 (m, 1H), 6.91 (s, 1H), 6.80-6.70 (m, 4H), 6.58 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.45 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.26 (d, J = 9.8 Hz, 1H), 6.09 (d, J = 1.8 Hz, 1H), 5.89 (d, J = 8.0 Hz, 1H), 5.82 (dd, J = 9.8 Hz, 5.4 Hz, 1H), 4.96 (d, J = 5.2 Hz, 1H) 4.42-4.30 (m, 2H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.6, 161.2, 144.6, 144.2, 141.9, 137.4, 135.5, 135.0, 133.6, 130.0, 129.8, 128.7, 128.6, 127.9, 127.8, 127.6, 127.0, 126.7, 125.5, 125.0, 124.9, 122.2, 121.6, 121.5, 121.1, 118.1, 114.3, 114.1, 113.8, 113.7, 113.5, 59.5, 50.3, 21.64, 21.5, IR (KBr) ν 3063, 2925, 1638, 1597, 1488, 1447, 1360, 1341, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{FN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 703.1975, found: 703.1973.

(E)-N-benzyl-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3af):




White solid (95%); m.p. 199.8-201.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.74 (t, J = 8.3 Hz, 4H), 7.37 (d, J = 8.0 Hz, 2H), 7.28-7.26 (m, 2H), 7.25-7.23 (m, 2H), 7.20-7.18 (m, 3H), 7.11-7.07 (m, 5H), 6.76 (s, 1H), 6.70 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.60 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.47 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.19 (dd, J = 9.8 Hz, 5.6 Hz, 1H), 6.07-6.04 (m, 1H), 5.90 (d, J = 8.0 Hz, 1H), 5.44 (d, J = 5.6 Hz, 1H), 5.21 (d, J = 1.8 Hz, 1H), 4.29-4.19 (m, 2H), 4.09-4.05 (m, 1H), 3.78 (m, 1H), 2.46 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 143.8, 141.6, 135.7, 135.6, 134.2, 134.0, 130.1, 130.0, 129.4, 128.6, 128.4, 128.1, 128.0, 127.9, 127.6, 127.0, 126.6, 125.3, 125.0, 124.5, 123.0, 122.5, 121.8, 118.3, 114.8, 60.4, 55.8, 50.8, 21.62, 21.58; IR (KBr) ν 3059, 3029, 2920, 1633, 1596, 1485, 1450, 1344, 1165 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 699.2225, found: 699.2222.

(E)-N-butyl-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3ag):



Light yellow solid (95%); m.p. 132.3-133.8°C; ^1H NMR (400 MHz, CDCl_3) δ 7.78 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.35-7.32 (m, 4H), 7.28 (d, J = 8.0 Hz, 2H), 7.24-7.18 (m, 3H), 6.88-6.86 (m, 2H), 6.70 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 6.59-6.55 (m, 1H), 6.51-6.47 (m, 1H), 6.41-6.38 (m, 1H), 6.09-6.07 (m, 1H), 5.60 (d, J = 5.5 Hz, 1H), 5.09 (d, J = 1.6 Hz, 1H), 4.37-4.35 (m, 1H), 4.25-4.22 (m, 1H), 3.12-3.05 (m, 1H), 2.54-2.47 (m, 1H), 2.43 (s, 3H), 2.38 (s, 3H), 1.33-1.27 (m, 2H), 1.19-1.10 (m, 2H), 0.74 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 143.8, 142.8, 141.5, 135.7, 135.5, 133.9, 130.1, 129.8, 128.6, 128.2, 128.1, 127.7, 127.68, 127.1, 126.5, 125.5, 125.4, 124.6, 123.7, 123.0, 121.6, 118.6, 115.4, 60.2, 51.2, 50.9, 29.78, 21.5, 20.1, 13.6; IR (KBr) ν 3057, 2954, 2929, 2868, 1635, 1596, 1482, 1346, 1162 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{38}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 665.2382, found: 665.2382.


(E)-2-nitro-N-phenyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3ah):



Yellow solid (43%); m.p. 200.6-202.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, J = 8.4 Hz, 2H), 7.64-7.60 (m, 2H), 7.54-7.49 (m, 2H), 7.20-7.18 (m, 7H), 7.13-7.10 (m, 5H), 6.95 (s, 1H), 6.69 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.56 (td, J = 7.7 Hz, 1.5 Hz, 1H), 6.49


(d, $J = 1.7$ Hz, 1H), 6.42 (td, $J = 7.4$ Hz, 1.0 Hz, 1H), 6.25 (d, $J = 9.8$ Hz, 1H), 5.86 (d, $J = 8.0$ Hz, 1H), 5.57 (q, $J = 5.0$ Hz, 1H), 4.94 (d, $J = 5.0$ Hz, 1H) 4.46-4.36 (m, 2H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 144.1, 142.2, 138.6, 135.5, 135.4, 135.1, 134.4, 132.1, 131.2, 130.05, 129.96, 129.4, 128.9, 128.6, 128.0, 127.5, 127.3, 126.94, 126.87, 126.8, 125.8, 125.1, 124.8, 124.0, 122.9, 121.1, 120.1, 117.7, 113.0, 59.2, 49.9, 21.5, IR (KBr) ν 3063, 2926, 1640, 1597, 1546, 1491, 1362, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{39}\text{H}_{32}\text{N}_4\text{O}_6\text{S}_2$ $[\text{M}]^+$: 716.1763, found: 716.1767.

(*E*)-*N*-phenyl-*N*-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)methanesulfonamide (3ai):




Yellow Off-white solid (92%); m.p. 102.2-104.1 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 8.4$ Hz, 2H), 7.25-7.17 (m, 11H), 7.11-7.15 (m, 1H), 7.05 (s, 1H), 6.71 (dd, $J = 7.4$ Hz, 1.4 Hz, 1H), 6.57 (td, $J = 7.8$ Hz, 1.6 Hz, 1H), 6.44 (td, $J = 7.4$ Hz, 1.0 Hz, 1H), 6.37 (d, $J = 2.0$ Hz, 1H), 6.23 (d, $J = 9.8$ Hz, 1H), 5.88 (d, $J = 8.0$ Hz, 1H), 5.59 (dd, $J = 9.8$ Hz, 5.4 Hz, 1H), 4.73-4.75 (m, 1H) 4.38 (s, 2H), 2.87 (s, 3H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.1, 142.1, 139.1, 135.5, 135.0, 133.3, 129.9, 129.5, 128.8, 128.5, 127.55, 127.49, 127.4, 126.9, 126.7, 126.0, 125.4, 124.9, 124.7, 122.7, 121.2, 120.4, 117.8, 113.2, 59.0, 50.3, 36.9, 21.5, IR (KBr) ν 3061, 2925, 1637, 1593, 1488, 1451, 1346, 1160 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{34}\text{H}_{31}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 609.1756, found: 609.1755.

(*E*)-3-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)oxazolidin-2-one (3aj):




Off-white solid (89%); m.p. 163.7-165.4 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.38-7.36 (m, 2H), 7.28-7.26 (m, 2H), 7.24-7.20 (m, 3H), 7.03 (s, 1H), 6.87 (dd, $J = 7.4$ Hz, 1.4 Hz, 1H), 6.74 (td, $J = 7.8$ Hz, 1.6 Hz, 1H), 6.57 (td, $J = 7.4$ Hz, 1.0 Hz, 1H), 6.37 (d, $J = 9.8$ Hz, 1H), 6.13 (d, $J = 8.0$ Hz, 1H), 5.88 (d, $J = 1.8$ Hz, 1H), 5.67 (dd, $J = 9.8$ Hz, 5.6 Hz, 1H), 5.23 (d, $J = 5.6$ Hz, 1H) 4.41 (s, 2H), 4.40-4.35 (m, 2H), 3.73-3.67 (m, 1H), 3.54-3.48 (m, 1H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.0, 144.1, 142.0, 135.6, 135.4, 130.3, 130.0, 129.0, 128.7, 127.6, 127.2, 127.1, 126.7, 125.4, 125.1, 122.5, 121.8, 121.4, 118.4, 114.6, 62.0, 59.7, 51.1, 45.7, 21.5, IR (KBr) ν 3058, 2988, 2918, 1760, 1667, 1599, 1490, 1450, 1160 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{30}\text{H}_{27}\text{N}_3\text{O}_4\text{S}$ $[\text{M}]^+$: 525.1722, found: 525.1722.

(*E*)-1-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)pyrrolidin-2-one (3ak):




Yellow solid (40%); m.p. 185.6-187.1 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.40-7.38 (m, 2H), 7.20-7.25 (m, 5H), 7.07 (s, 1H), 6.84 (dd, $J = 7.4$ Hz, 1.4 Hz, 1H), 6.70 (td, $J = 7.8$ Hz, 1.4 Hz, 1H), 6.54 (td, $J = 7.4$ Hz, 1.0 Hz, 1H), 6.32 (d, $J = 9.8$ Hz, 1H), 6.09 (d, $J = 8.0$ Hz, 1H), 5.98 (d, $J = 1.4$ Hz, 1H), 5.57 (dd, $J = 5.0$ Hz, 5.4 Hz, 1H), 5.36 (d, $J = 5.4$ Hz, 1H) 4.46-4.38 (m, 2H), 3.53-3.47 (m, 1H), 3.34-3.29 (m, 1H), 2.44-2.41 (m, 2H), 2.39 (s, 3H), 2.10-2.02 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.4, 143.9, 142.3, 135.8, 135.5, 129.9, 129.5, 129.0, 128.7, 127.5, 127.2, 126.8, 126.7, 125.3, 125.0, 122.9, 122.3, 121.7, 121.1, 118.1, 114.2, 60.0, 51.3, 48.4, 30.5, 21.5, 18.4; IR (KBr) ν 3061, 2923, 1707, 1649, 1598, 1491, 1449, 1339, 1157 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{31}\text{H}_{29}\text{N}_3\text{O}_3\text{S}$ $[\text{M}]^+$: 523.1930, found: 523.1932.

(E)-4-methyl-*N*-((9-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-*N*-phenylbenzenesulfonamide (3b*a*):




Off-white solid (91%); m.p. 192.6-194.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.25-7.23 (m, 2H), 7.21-7.15 (m, 7H), 7.12-7.09 (m, 3H), 6.93-6.91 (m, 2H), 6.88 (s, 1H), 6.54 (d, J = 1.8 Hz, 1H), 6.37 (dd, J = 8.2 Hz, 1.6 Hz, 1H), 6.23 (d, J = 9.8 Hz, 1H), 6.18 (d, J = 1.8 Hz, 1H), 5.84 (dd, J = 9.8 Hz, 5.6 Hz, 1H), 5.79 (d, J = 8.0 Hz, 1H), 4.84 (d, J = 5.4 Hz, 1H), 4.40-4.28 (m, 2H), 2.42 (s, 3H), 2.38 (s, 3H), 2.05 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 144.1, 139.8, 139.7, 135.7, 135.51, 135.5, 133.9, 129.9, 129.6, 129.1, 129.0, 128.5, 128.0, 127.9, 127.5, 127.4, 127.3, 127.1, 127.0, 126.7, 125.5, 125.2, 125.1, 122.1, 122.0, 121.2, 113.8, 59.4, 50.7, 21.62, 21.57, 20.2; IR (KBr) ν 3059, 2924, 1638, 1594, 1494, 1349, 1264, 1164 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 699.2225, found: 699.2224.

(E)-*N*-((9-methoxy-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3c*a*):




Light yellow solid (87%); m.p. 203.5-205.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.24-7.13 (m, 12H), 6.95-6.92 (m, 2H), 6.81 (s, 1H), 6.34 (d, J = 2.8 Hz, 1H), 6.25 (d, J = 9.8 Hz, 1H), 6.21 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 6.14 (d, J = 1.8 Hz, 1H), 6.03 (dd, J = 9.8 Hz, 5.8 Hz, 1H), 5.88 (d, J = 8.8 Hz, 1H), 4.80 (d, J = 5.6 Hz, 1H), 4.43-4.39 (m, 1H), 4.29-4.25 (m, 1H), 3.60 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.4, 144.2, 144.1, 140.0, 136.6, 135.8, 135.64, 135.56, 133.8, 130.0, 129.6, 129.0, 128.5, 128.4, 127.9, 127.6, 127.3, 127.1, 126.5, 125.4, 124.9, 123.4, 123.1, 121.2, 115.5, 113.9, 112.2, 60.4, 59.5, 55.5, 51.3, 21.63, 21.58; IR (KBr) ν 3057, 2930, 1635, 1596, 1491, 1448, 1354, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_5\text{S}_2$ $[\text{M}]^+$: 715.2175, found: 715.2175.

(E)-methyl 5-((4-methyl-*N*-phenylphenylsulfonamido)methylene)-1-phenyl-3-tosyl-3,4,5*a*-tetrahydro-[1,4]diazepino[1,7-*a*]quinoline-9-carboxylate (3d*a*):




Off-white solid (91%); m.p. 130.1-131.8°C; ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 2.0 Hz, 1H), 7.24 (m, 2H), 7.19-7.16 (m, 3H), 7.13 (d, J = 8.0 Hz, 2H), 7.11-7.08 (m, 3H), 7.05 (s, 1H), 7.01-6.98 (m, 3H), 6.91-6.89 (m, 2H), 6.38 (d, J = 1.6 Hz, 1H), 6.23 (dd, J = 10.0 Hz, 0.8 Hz, 1H), 5.63 (d, J = 8.6 Hz, 1H), 5.46 (dd, J = 10.0 Hz, 4.6 Hz, 1H), 4.85 (d, J = 4.6 Hz, 1H), 4.42-4.39 (m, 1H), 4.31-4.28 (m, 1H), 3.79 (s, 3H), 2.43 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.8, 147.0, 144.6, 144.5, 139.1, 135.1, 133.9, 133.7, 131.3, 130.3, 129.9, 129.7, 129.2, 128.8, 128.4, 127.9, 127.8, 127.3, 127.2, 126.8, 126.7, 125.2, 124.3, 124.0, 121.6, 118.5, 118.1, 110.8, 58.9, 51.5, 49.3, 21.6; 21.4 IR (KBr) ν 3060, 2949, 1710, 1645, 1599, 1495, 1446, 1359, 1279, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{42}\text{H}_{37}\text{N}_3\text{O}_6\text{S}_2$ $[\text{M}]^+$: 743.2124, found: 743.2126.

(E)-N-((9-bromo-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ea)




Off-white solid (91%); m.p. 122.9-124.2°C; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.23-7.25 (m, 2H), 7.20-7.17 (m, 5H), 7.13-7.11 (m, 2H), 7.06-7.04 (m, 3H), 6.96 (s, 1H), 6.92-6.90 (m, 2H), 6.77 (d, *J* = 2.4 Hz, 1H), 6.52 (dd, *J* = 8.6 Hz, 2.4 Hz, 1H), 6.28 (d, *J* = 1.8 Hz, 1H), 6.16 (d, *J* = 9.8 Hz, 1H), 5.67 (dd, *J* = 9.8 Hz, 5.2 Hz, 1H), 5.62 (d, *J* = 8.8 Hz, 1H), 4.84 (d, *J* = 5.0 Hz, 1H), 4.43-4.40 (m, 1H), 4.29-4.26 (m, 1H), 2.43 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.44, 144.39, 141.6, 139.4, 135.4, 134.5, 133.7, 132.8, 131.2, 129.9, 129.7, 129.1, 128.9, 128.7, 127.8, 127.74, 127.67, 127.5, 126.9, 126.8, 126.2, 124.7, 124.3, 123.2, 122.9, 121.8, 114.2, 109.5, 58.9, 50.0, 21.62, 21.60; IR (KBr) ν 3060, 2925, 1641, 1596, 1486, 1353, 1264, 1165 cm⁻¹; HRMS (EI) *m/z* calcd. for C₄₀H₃₄BrN₃O₄S₂ [M]⁺: 763.1174, found: 763.1177.

(E)-N-((9-chloro-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3fa)




Off-white solid (93%); m.p. 188.5-190.1°C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.23-7.25 (m, 2H), 7.19-7.17 (m, 5H), 7.14-7.11 (m, 2H), 7.07-7.05 (m, 3H), 6.95 (s, 1H), 6.92-6.90 (m, 2H), 6.64 (d, *J* = 2.4 Hz, 1H), 6.39 (dd, *J* = 8.6 Hz, *J*₂ = 2.6 Hz, 1H), 6.27 (d, *J* = 1.8 Hz, 1H), 6.16 (d, *J* = 9.8 Hz, 1H), 5.72-5.67 (m, 2H), 4.84 (d, *J* = 5.2 Hz, 1H), 4.43-4.40 (m, 1H), 4.30-4.26 (m, 1H), 2.43 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.4, 141.0, 139.4, 135.4, 134.6, 133.7, 133.0, 129.9, 129.7, 129.1, 128.6, 128.2, 127.8, 127.7, 127.6, 126.8, 126.13, 126.11, 124.7, 124.4, 123.05, 123.01, 122.4, 121.5, 113.8, 58.9, 50.1, 21.6, 21.5; IR (KBr) ν 3060, 2925, 1639, 1596, 1487, 1350, 1265, 1164 cm⁻¹; HRMS (EI) *m/z* calcd. for C₄₀H₃₄ClN₃O₄S₂ [M]⁺: 719.1679, found: 719.1682.

(E)-4-methyl-N-((10-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ga):




Off-white solid (87%); m.p. 122.3-124.0°C; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.25-7.23 (m, 2H), 7.20-7.15 (m, 7H), 7.08-7.06 (m, 3H), 6.95 (s, 1H), 6.90-6.88 (m, 2H), 6.61 (d, *J* = 7.6 Hz, 1H), 6.27-6.25 (m, 1H), 6.22 (d, *J* = 9.8 Hz, 1H), 6.19 (d, *J* = 1.8 Hz, 1H), 5.75 (s, 1H), 5.68 (dd, *J* = 9.8 Hz, 5.2 Hz, 1H), 4.84 (d, *J* = 5.2 Hz, 1H), 4.38 (s, 2H), 2.42 (s, 3H), 2.36 (s, 3H), 1.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.3, 144.0, 142.2, 139.6, 138.6, 135.8, 135.4, 134.8, 134.0, 129.9, 129.7, 129.0, 128.6, 127.8, 127.5, 127.4, 127.0, 126.8, 126.7, 125.6, 125.2, 124.9, 122.6, 121.7, 120.6, 118.9, 118.4, 114.1, 59.5, 50.4, 21.63, 21.56, 21.1; IR (KBr) ν 3046, 2923, 1634, 1595, 1497, 1445, 1352, 1266, 1164 cm⁻¹; HRMS (EI) *m/z* calcd. for C₄₁H₃₇N₃O₄S₂ [M]⁺: 699.2225, found: 699.2226.

(E)-N-((8-bromo-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ha):




Light-yellow solid (88%); m.p. 177.9-179.5°C; ^1H NMR (400 MHz, CDCl_3) δ 7.71 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.27 (m, 1H), 7.25-7.22 (m, 3H), 7.18-7.16 (m, 5H), 7.12-7.10 (m, 3H), 6.93-6.90 (m, 3H), 6.71-6.66 (m, 2H), 6.40 (t, $J = 8.0$ Hz, 1H), 6.20 (d, $J = 1.8$ Hz, 1H), 5.97 (dd, $J = 10.0$ Hz, 5.6 Hz, 1H), 5.87 (d, $J = 8.2$ Hz, 1H), 4.92 (d, $J = 5.4$ Hz, 1H), 4.43-4.40 (m, 1H), 4.29-4.25 (m, 1H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.34, 144.27, 143.4, 139.5, 135.7, 134.8, 135.7, 134.1, 130.1, 129.7, 129.2, 129.1, 128.7, 127.9, 127.8, 127.7, 127.3, 127.0, 126.8, 126.1, 124.9, 123.8, 123.6, 122.6, 122.15, 122.1, 120.4, 113.3, 59.3, 50.6, 21.63, 21.58; IR (KBr) ν 3059, 2926, 1636, 1591, 1554, 1496, 1445, 1352, 1163 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{BrN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 763.1174, found: 763.1176.

(E)-N-((8-chloro-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ia):




Off-white solid (90%); m.p. 103.6-105.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.27 (m, 1H), 7.25-7.23 (m, 2H), 7.21 (m, 1H), 7.18-7.15 (m, 5H), 7.11-7.10 (m, 3H), 6.93-6.90 (m, 3H), 6.71 (d, $J = 10.4$ Hz, 1H), 6.50-6.44 (m, 2H), 6.22 (d, $J = 1.6$ Hz, 1H), 5.92 (dd, $J = 10.0$ Hz, 5.6 Hz, 1H), 5.82-5.80 (m, 1H), 4.90 (d, $J = 5.4$ Hz, 1H), 4.42-4.39 (m, 1H), 4.30-4.26 (m, 1H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.3, 144.2, 143.3, 139.5, 135.6, 134.8, 134.4, 134.0, 130.4, 130.0, 129.7, 129.1, 128.70, 128.66, 127.8, 127.72, 127.68, 127.4, 127.0, 126.8, 126.1, 124.9, 123.2, 122.6, 121.2, 118.8, 118.7, 112.4, 59.2, 50.5, 21.6, 21.5; IR (KBr) ν 3060, 2925, 1634, 1589, 1496, 1448, 1349, 1266, 1163 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{ClN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 719.1679, found: 719.1679.

(E)-N-((1,6-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ja, E-isomer):



Yellow solid (38%); m.p. 169.3-171.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.2$ Hz, 2H), 7.31-7.27 (m, 3H), 7.25-7.23 (m, 2H), 7.20-7.18 (m, 5H), 7.15-7.08 (m, 8H), 6.96-6.92 (m, 3H), 7.90-7.87 (m, 2H), 6.79-6.76 (m, 1H), 6.72 (d, $J = 7.6$ Hz, 2H), 6.21 (d, $J = 8.0$ Hz, 1H), 5.88 (s, 1H), 4.93 (d, $J = 17.2$ Hz, 1H), 4.73 (s, 1H), 3.43 (d, $J = 17.2$ Hz, 1H), 2.43 (s, 3H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.9, 143.6, 141.0, 139.6, 137.5, 136.2, 135.5, 134.0, 132.7, 131.5, 130.1, 129.4, 129.3, 129.1, 128.6, 128.5, 128.0, 127.8, 127.7, 127.6, 127.1, 127.0, 126.8, 126.2, 125.4, 125.0, 123.1, 120.0, 119.2, 118.0, 61.7, 48.2, 21.9, 21.6; IR (KBr) ν 3059, 3029, 2922, 1650, 1593, 1485, 1354, 1266, 1165 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{46}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 761.2382, found: 761.2384.


(Z)-N-((1,6-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ja, Z-isomer):



Off-white solid (54%); m.p. 224.7-226.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, $J = 8.2$ Hz, 2H), 7.48 (d, $J = 8.0$ Hz, 2H), 7.38-7.36 (m, 3H), 7.20-7.18 (m, 2H), 7.15-7.08 (m, 10H), 7.01-6.97 (m, 2H), 6.95 (s, 1H), 6.73 (td, $J = 7.8$ Hz, 1.2 Hz, 1H), 6.50 (td, $J = 7.4$ Hz, 1.0 Hz, 1H), 6.33 (d, $J = 7.6$ Hz, 2H), 6.28 (d, $J = 6.6$ Hz, 1H), 6.19 (d, $J = 8.0$


Hz, 1H), 6.06 (s, 1H), 6.03 (s, 1H), 4.76-4.72 (m, 2H), 4.24-4.21 (m, 1H), 2.53 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.0, 143.9, 142.7, 139.5, 136.9, 136.1, 135.7, 135.1, 132.0, 130.5, 129.9, 129.2, 128.6, 128.5, 128.1, 128.0, 127.8, 127.59, 127.56, 126.6, 126.1, 125.9, 125.8, 125.3, 124.5, 122.3, 119.5, 119.3, 116.6, 61.0, 54.0, 21.9, 21.5; IR (KBr) ν 3054, 3029, 2921, 1625, 1595, 1485, 1445, 1353, 1164 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{46}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 761.2382, found: 761.2383.

(E)-4-methyl-N-((6-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ka):




White solid (96%); m.p. 243.2-245.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.16-7.10 (m, 5H), 7.07-7.05 (m, 2H), 7.00 (s, 1H), 6.89-6.86 (m, 2H), 6.84-6.81 (m, 3H), 6.41-6.37 (m, 2H), 6.34-6.25 (m, 2H), 5.89 (s, 1H), 5.62 (d, J = 7.8 Hz, 1H), 4.45-4.42 (m, 2H), 4.25-4.22 (m, 1H), 2.41 (s, 3H), 2.36 (s, 3H), 1.85 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 143.9, 141.3, 139.9, 135.3, 134.4, 133.0, 129.9, 129.6, 129.5, 128.9, 128.8, 128.6, 128.5, 127.9, 127.8, 127.5, 127.4, 127.1, 126.8, 126.7, 125.8, 124.4, 123.3, 122.4, 119.9, 117.0, 111.6, 61.4, 50.2, 21.6, 21.5, 21.0; IR (KBr) ν 3059, 3029, 2919, 1594, 1485, 1444, 1349, 1264, 1163 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 699.2225, found: 699.2226.

(E)-4-methyl-N-phenyl-N-((1-(*p*-tolyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3la):



Yellow solid (96%); m.p. 108.0-109.6°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.25-7.23 (m, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.11-7.06 (m, 5H), 6.98-6.96 (m, 2H), 6.93-6.91 (m, 2H), 6.87 (s, 1H), 6.69 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.54 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.42 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.24 (d, J = 9.8 Hz, 1H), 6.20 (d, J = 1.8 Hz, 1H), 5.83 (d, J = 8.0 Hz, 1H), 5.75 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.40-4.30 (m, 2H), 2.42 (s, 3H), 2.36 (s, 3H), 2.27 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 144.0, 142.1, 139.7, 137.4, 135.5, 134.9, 133.8, 132.3, 129.9, 129.6, 129.2, 129.0, 128.7, 127.9, 127.8, 127.4, 126.9, 126.7, 126.6, 125.5, 125.2, 124.9, 121.7, 121.6, 120.8, 117.8, 113.5, 59.4, 50.4, 21.6, 21.5, 21.1; IR (KBr) ν 3045, 2922, 1639, 1593, 1490, 1350, 1165 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 699.2225, found: 699.2226.


(E)-N-((1-(4-bromophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ma):



Off-white solid (98%); m.p. 121.3-123.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.29-7.26 (m, 2H), 7.25-7.23 (m, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.12-7.10 (m, 3H), 7.05-7.03 (m, 2H), 6.93-6.90 (m, 3H), 6.71 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.56 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.45 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.25 (d, J = 10.0 Hz, 1H), 6.21 (d, J = 1.8 Hz, 1H), 5.81 (d, J = 8.0 Hz, 1H), 5.76 (dd, J = 9.8 Hz, 5.3 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.39-4.29 (m, 2H), 2.43 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.3, 144.2, 141.8, 139.6, 135.5, 134.5, 134.3, 133.8, 131.7, 130.0, 129.7, 129.1, 128.8,


127.8, 127.6, 126.9, 126.8, 126.7, 126.6, 126.4, 125.8, 125.2, 123.0, 121.7, 121.2, 120.8, 118.1, 113.2, 59.3, 50.3, 21.6, 21.5; IR (KBr) ν 3063, 2923, 1487, 1356, 1343, 1263, 1164, 1089 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{BrN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 703.1975, found: 703.1979.

(*E*)-*N*-((1-(3-fluorophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3na):




Light-yellow solid (93%); m.p. 188.5-190.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.24 (m, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.16-7.13 (m, 1H), 7.11-7.08 (m, 3H), 6.99-6.97 (m, 2H), 6.93-6.90 (m, 2H), 6.86-6.81 (m, 2H), 6.71 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.56 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.45 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.25 (d, J = 10.0 Hz, 1H), 6.22 (d, J = 1.8 Hz, 1H), 5.82 (d, J = 8.0 Hz, 1H), 5.72 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.39-4.30 (m, 2H), 2.43 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3, 161.9, 144.4, 144.3, 142.1, 139.6, 137.95, 137.88, 135.5, 134.1, 133.8, 130.0, 129.7, 129.1, 128.8, 127.9, 127.6, 126.93, 126.87, 127.4, 125.9, 125.4, 123.9, 121.6, 120.6, 120.4, 118.1, 114.4, 114.2, 113.0, 111.7, 111.5, 59.3, 50.3, 21.63, 21.57; IR (KBr) ν 3064, 2924, 1637, 1597, 1454, 1351, 1163 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{34}\text{FN}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 703.1975, found: 703.1979.

(*E*)-*N*-((1-(3-fluorophenyl)-9-methoxy-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3oa):



Light-yellow solid (91%); m.p. 165.6-167.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.25-7.23 (m, 4H), 7.17-7.11 (m, 4H), 7.00 (d, J = 7.8 Hz, 1H), 6.94-6.92 (m, 2H), 6.87-6.82 (m, 3H), 6.35 (d, J = 2.8 Hz, 1H), 6.27-6.21 (m, 2H), 6.14 (d, J = 1.4 Hz, 1H), 6.02 (dd, J = 9.8 Hz, 5.7 Hz, 1H), 5.87 (d, J = 8.8 Hz, 1H), 4.80 (d, J = 5.4 Hz, 1H), 4.41-4.24 (m, 2H), 3.62 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2, 161.8, 152.5, 144.3, 139.9, 138.4, 138.3, 136.1, 135.6, 135.4, 133.8, 130.1, 130.0, 129.9, 129.6, 129.0, 127.8, 127.4, 127.0, 126.5, 125.6, 124.9, 123.3, 123.0, 122.4, 120.8, 120.7, 115.1, 114.4, 114.2, 113.9, 112.3, 112.1, 111.9, 59.4, 55.5, 51.1, 21.6, 21.5; IR (KBr) ν 3062, 2929, 1493, 1356, 1269, 1242, 1165, 1090 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{36}\text{FN}_3\text{O}_5\text{S}_2$ $[\text{M}]^+$: 721.1881, found: 721.1880.


(*E*)-4-methyl-*N*-phenyl-*N*-((3-tosyl-1-(3-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3pa):



Yellow solid (81%); m.p. 121.1-123.0°C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.43-7.40 (m, 5H), 7.29-7.28 (m, 1H), 7.24-7.18 (m, 4H), 7.05-7.03 (m, 4H), 6.92-6.90 (m, 2H), 6.71 (d, J = 6.4 Hz, 1H), 6.56-6.52 (m, 1H), 6.46-6.43 (m, 1H), 6.28-6.23 (m, 2H), 5.79 (d, J = 8.0 Hz, 1H), 5.72 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.85 (d, J = 5.0 Hz, 1H), 4.41-4.32 (m, 2H), 2.43 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.42, 144.38, 142.1, 139.6, 136.3, 135.5, 133.8, 133.7, 130.1, 129.7, 129.2, 129.1, 128.9, 128.0, 127.8, 127.6, 127.0, 126.93, 126.89, 126.1, 125.4, 124.5, 124.11, 124.07, 122.6, 121.6, 121.3,


120.5, 118.1, 112.7, 59.1, 50.2, 21.61, 21.56; IR (KBr) ν 3065, 2925, 1638, 1594, 1489, 1333, 1258, 1165, 1126 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{34}\text{F}_3\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 753.1943, found: 753.1945.

(*E*)-4-methyl-*N*-phenyl-*N*-((3-tosyl-1-(4-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7- α]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3qa):




Off-white solid (95%); m.p. 184.7-186.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.43-7.40 (m, 4H), 7.28 (m, 2H), 7.24 (m, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.10-7.06 (m, 4H), 6.91-6.89 (m, 2H), 6.73 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.57 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.46 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.26 (d, J = 10.0 Hz, 1H), 6.22 (d, J = 1.8 Hz, 1H), 5.81 (d, J = 8.0 Hz, 1H), 5.74 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.89 (d, J = 5.2 Hz, 1H) 4.41-4.33 (m, 2H), 2.43 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 141.9, 139.6, 139.0, 135.5, 134.1, 133.8, 130.1, 129.7, 129.4, 129.1, 128.9, 127.8, 127.6, 127.0, 126.9, 126.8, 126.0, 125.9, 125.63, 125.59, 125.5, 125.4, 124.9, 124.8, 121.7, 120.7, 118.2, 112.9, 59.3, 50.3, 21.62, 21.58; IR (KBr) ν 3064, 2924, 1639, 1599, 1490, 1451, 1359, 1321, 1166 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{41}\text{H}_{34}\text{F}_3\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 753.1943, found: 753.1941.

(*E*)-4-methyl-*N*-((10-methyl-3-tosyl-1-(4-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7- α]quinolin-5(5*aH*)-ylidene)methyl)-*N*-phenylbenzenesulfonamide (3ra):



Off-white solid (91%); m.p. 220.4-222.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, J = 8.4 Hz, 2H), 7.43-7.40 (m, 4H), 7.28 (d, J = 8.4 Hz, 2H), 7.23 (m, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.09 (s, 1H), 7.08-7.06 (m, 3H), 6.89-6.86 (m, 2H), 6.63 (d, J = 7.4 Hz, 1H), 6.30 (dd, J = 7.6 Hz, 0.8 Hz, 1H), 6.24 (d, J = 9.8 Hz, 1H), 6.20 (d, J = 1.8 Hz, 1H), 5.71 (s, 1H), 5.67 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H) 4.39 (s, 2H), 2.43 (s, 3H), 2.36 (s, 3H), 1.92 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.35, 144.30, 141.9, 139.6, 139.1, 138.8, 135.7, 134.4, 133.9, 130.0, 129.7, 129.05, 128.96, 127.8, 127.5, 127.0, 126.9, 126.8, 125.9, 125.62, 125.58, 125.5, 125.3, 124.9, 124.8, 120.6, 119.2, 118.3, 113.7, 59.5, 50.2, 21.64, 21.62, 21.58; IR (KBr) ν 3045, 2924, 1605, 1496, 1354, 1325, 1167, 1113 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{42}\text{H}_{36}\text{F}_3\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 767.2099, found: 767.2097.


(*E*)-*N*-((1-(3,5-difluorophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7- α]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3sa):



Off-white solid (96%); m.p. 178.6-180.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.27 (m, 1H), 7.24 (m, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.13-7.11 (m, 3H), 7.00 (s, 1H), 6.93-6.90 (m, 2H), 6.73 (dd, J = 7.4 Hz, 1.4 Hz, 1H), 6.69-6.66 (m, 2H), 6.61-6.56 (m, 2H), 6.47 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.25 (d, J = 10.0 Hz, 1H), 6.22 (d, J = 1.8 Hz, 1H), 5.81 (d, J = 8.0 Hz, 1H), 5.71 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.85 (d, J = 5.2 Hz, 1H), 4.38-4.29 (m, 2H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.5, 164.4, 162.1, 162.0, 144.44, 144.41, 141.9, 139.6, 139.4, 135.5, 133.8, 133.7, 130.1, 129.7, 129.1, 128.9, 127.8, 127.6, 127.0, 126.9, 126.1, 125.4, 125.1, 121.6, 120.6, 118.3, 112.7, 107.5, 107.2, 102.9,


102.6, 102.4, 59.2, 50.2, 21.62, 21.58; IR (KBr) ν 3065, 2924, 1613, 1594, 1484, 1444, 1345, 1164 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{33}\text{F}_2\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 721.1881, found: 721.1880.

(*E*)-*N*-((1-(3,5-bis(trifluoromethyl)phenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3ta):




Yellow solid (85%); m.p. 125.4-127.1°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66-7.64 (m, 3H), 7.51 (m, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.27 (m, 1H), 7.24 (m, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.14 (s, 1H), 7.05-7.03 (m, 3H), 6.91-6.89 (m, 2H), 6.74 (dd, J = 7.4 Hz, 1.6 Hz, 1H), 6.55 (td, J = 7.6 Hz, 1.6 Hz, 1H), 6.47 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.28 (d, J = 10.0 Hz, 1H), 6.24 (d, J = 1.8 Hz, 1H), 5.77 (d, J = 8.0 Hz, 1H), 5.72 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.83 (d, J = 5.2 Hz, 1H), 4.42-4.32 (m, 2H), 2.43 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.6, 144.5, 141.9, 139.6, 138.1, 135.4, 133.7, 133.0, 132.2, 131.9, 130.1, 129.7, 129.6, 129.3, 129.1, 129.0, 127.8, 127.6, 127.3, 127.0, 126.9, 126.4, 126.3, 125.5, 124.5, 124.3, 121.8, 121.7, 121.6, 120.8, 120.5, 118.6, 112.2, 58.9, 50.1, 21.62, 21.58; IR (KBr) ν 3064, 2925, 1635, 1595, 1484, 1354, 1276, 1164, 1135 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{42}\text{H}_{33}\text{F}_6\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 821.1817, found: 821.1821.

(*E*)-4-methyl-*N*-phenyl-*N*-((1-phenyl-3-((4-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ua):



Light-yellow solid (94%); m.p. 104.5-106.5°C; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.24 (m, 2H), 7.20-7.16 (m, 5H), 7.07-7.05 (m, 3H), 6.93-6.91 (m, 3H), 6.67 (dd, J = 7.2 Hz, 1.6 Hz, 1H), 6.45 (td, J = 7.8 Hz, 1.6 Hz, 1H), 6.39 (td, J = 7.2 Hz, 1.0 Hz, 1H), 6.31 (d, J = 1.6 Hz, 1H), 6.23 (d, J = 10.0 Hz, 1H), 5.72 (d, J = 8.0 Hz, 1H), 5.64 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.81 (d, J = 5.0 Hz, 1H), 4.48-4.45 (m, 1H), 4.39-4.35 (m, 1H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 142.1, 141.9, 139.4, 134.9, 134.5, 133.8, 132.9, 129.7, 129.6, 129.1, 128.8, 128.6, 127.9, 127.8, 127.7, 127.4, 126.9, 126.8, 126.5, 126.4, 126.2, 125.5, 125.0, 121.9, 121.3, 120.1, 118.0, 112.6, 58.8, 50.6, 21.6; IR (KBr) ν 3068, 2925, 1640, 1597, 1490, 1449, 1358, 1321, 1171 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{32}\text{F}_3\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 739.1786, found: 739.1789.


(*E*)-4-methyl-*N*-phenyl-*N*-((1-phenyl-3-(phenylsulfonyl)-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3va):



Light-yellow solid (83%); m.p. 100.8-102.3°C; ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, J = 7.4 Hz, 2H), 7.54-7.51 (m, 1H), 7.43-7.40 (m, 4H), 7.23-7.25 (m, 2H), 7.19-7.15 (m, 5H), 7.10-7.08 (m, 3H), 6.96-6.93 (m, 3H), 6.70 (dd, J = 7.4 Hz, 1.2 Hz, 1H), 6.58-6.53 (m, 1H), 6.44-6.40 (m, 1H), 6.24 (d, J = 10.0 Hz, 1H), 6.22 (d, J = 1.6 Hz, 1H), 5.85 (d, J = 8.0 Hz, 1H), 5.74 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.41-4.32 (m, 2H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.3, 142.1, 139.7, 138.6, 135.1, 134.6, 133.9, 133.2, 129.7, 129.4, 129.1, 128.8, 128.6, 128.0, 127.9, 127.6, 127.5, 126.9, 126.82, 126.78, 125.8, 125.3, 125.0,


122.5, 121.7, 120.8, 118.1, 113.4, 59.4, 50.5, 21.6; IR (KBr) ν 3065, 2924, 1639, 1595, 1489, 1446, 1347, 1163 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{39}\text{H}_{33}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}]^+$: 671.1912, found: 671.1910.

(E)-4-methyl-N-phenyl-N-((1-phenyl-3-tosyl-3,4,6,7-tetrahydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (4aa):



White solid (96%); m.p. 119.6-121.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.2 Hz, 2H), 7.41 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.10-7.06 (m, 6H), 6.96-6.92 (m, 4H), 6.81 (d, J = 7.2 Hz, 1H), 6.76 (s, 1H), 6.57-6.53 (m, 2H), 6.44 (t, J = 7.2 Hz, 1H), 5.78 (d, J = 8.0 Hz, 1H), 4.23-4.20 (m, 1H), 4.12-4.05 (m, 2H), 2.69-2.62 (m, 1H), 2.60-2.52 (m, 1H), 2.42 (s, 3H), 2.35 (s, 3H), 2.04-2.00 (m, 1H), 1.96-1.88 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.3, 144.0, 143.1, 139.3, 136.2, 135.3, 133.7, 130.9, 129.9, 129.6, 129.5, 129.1, 128.7, 128.4, 128.2, 127.8, 127.7, 127.3, 127.1, 126.9, 126.7, 124.9, 122.7, 121.9, 117.3, 114.7, 58.9, 49.0, 27.0, 25.8, 21.6, 21.5; IR (KBr) ν 3060, 2925, 1639, 1600, 1489, 1349, 1165 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{40}\text{H}_{37}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}^+]$: 687.2225, found: 687.2226.

(E)-N-((1,9-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (5ea):





Off-white solid (56%); m.p. 207.8-209.2°C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.38-7.31 (m, 5H), 7.23-7.22 (m, 2H), 7.21-7.18 (m, 5H), 7.15 (d, J = 8.2 Hz, 2H), 7.08-7.07 (m, 3H), 6.99 (s, 1H), 6.95-6.92 (m, 3H), 6.76 (dd, J = 8.2 Hz, 2.0 Hz, 1H), 6.31 (d, J = 9.8 Hz, 1H), 6.27 (d, J = 1.6 Hz, 1H), 5.89 (d, J = 8.4 Hz, 1H), 5.74 (dd, J = 9.8 Hz, 5.2 Hz, 1H), 4.89 (d, J = 5.0 Hz, 1H), 4.44-4.35 (m, 2H), 2.43 (s, 3H), 2.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.4, 144.2, 142.0, 140.7, 139.6, 135.6, 135.1, 133.9, 133.8, 130.6, 129.9, 129.7, 129.1, 128.7, 128.6, 127.9, 127.7, 127.6, 127.4, 127.3, 126.95, 126.92, 126.2, 126.0, 125.9, 125.4, 125.3, 124.9, 123.0, 122.0, 120.6, 113.3, 59.3, 50.2, 21.6, 21.4; IR (KBr) ν 3059, 2983, 1650, 1560, 1456, 1341, 1162 cm^{-1} ; HRMS (EI) m/z calcd. for $\text{C}_{46}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$ $[\text{M}^+]$: 761.2382, found: 761.2379.

V. References



- S1. (a) L.-L. Wei, J. A. Mulder, H. Xiong, C. A. Zificksak, C. J. Douglas and R. P. Hsung, *Tetrahedron* 2001, **57**, 459; (b) A. Ballesteros, P. Morán-Poladura and J. M. González, *Chem. Commun.*, 2016, **52**, 2905; (c) H.-H. Li, X.-X. Li, Z.-G. Zhao, X. Yuan and C.-Y. Sun, *Org. Biomol. Chem.*, 2017, **15**, 4005.
- S2. J. Shin, J. Lee, D. Ko, N. De and E. J. Yoo, *Org. Lett.* 2017, **19**, 2901.

VI. Copies of Spectral Data of Compounds Obtained in this Study



2-nitro-N-phenyl-N-(prop-2-yn-1-yl)benzenesulfonamide:





(Z)-(2-phenyl-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1a):




(Z)-(2-(6-methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1b):




(Z)-(2-(6-methoxyquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1c):



(Z)-2-(6-(methoxycarbonyl)quinolin-1-ium-1-yl)-2-phenylvinyl(tosyl)amide (1d):




Current Data Parameters
NAME NO-161
EXPNO 2
PROCNO 2
F2 - Acquisition Parameters
Date_ 20170421
Time 20.13
INSTRUM spect
PROBHD 5 mm PABBO BBO
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
DS 4
SWH 24038.461 Hz
FIDRES 0.36078 Hz
AQ 1.3631688 sec
RG 156.03
SW 20.4600 usec
SF 297.301 MHz
WDW 2.0000000 sec
SSB 0.0300000 sec
LB 1
GB 0
PC 1.40





Current Data Parameters
NAME NO-161
EXPNO 2
PROCNO 2
F2 - Acquisition Parameters
Date_ 20170421
Time 20.13
INSTRUM spect
PROBHD 5 mm PABBO BBO
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
DS 4
SWH 24038.461 Hz
FIDRES 0.36078 Hz
AQ 1.3631688 sec
RG 156.03
SW 20.4600 usec
SF 297.301 MHz
WDW 2.0000000 sec
SSB 0.0300000 sec
LB 1
GB 0
PC 1.40



(Z)-(2-(6-bromoquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1e):





S-27





(Z)-(2-(7-methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1g):




(Z)-(2-(5-bromoquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1h):





(Z)-2-phenyl-2-(3-phenylquinolin-1-ium-1-yl)vinyl(tosyl)amide (1j):





(Z)-(2-(3-methylquinolin-1-ium-1-yl)-2-phenylvinyl)(tosyl)amide (1k):





S-33





(Z)-(2-(4-bromophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1m):





(Z)-(2-(3-fluorophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1n):





(Z)-(2-(3-fluorophenyl)-2-(6-methoxyquinolin-1-ium-1-yl)vinyl)(tosyl)amide (10a):




(Z)-2-(2-(quinolin-1-ium-1-yl)-2-(3-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1p):





(Z)-2-(2-(quinolin-1-ium-1-yl)-2-(4-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1q):









(Z)-(2-(7-methylquinolin-1-ium-1-yl)-2-(4-(trifluoromethyl)phenyl)vinyl)(tosyl)amide (1r):





(Z)-2-(2-(3,5-difluorophenyl)-2-(quinolin-1-ium-1-yl)vinyl)(tosyl)amide (1s):





(Z)-(2-(3,5-bis(trifluoromethyl)phenyl)-2-(quinolin-1-yl)vinyl)(tosyl)amide (1t):




(Z)-(2-phenyl-2-(quinolin-1-ium-1-yl)vinyl)((4-(trifluoromethyl)phenyl)sulfonyl)amide (1u):





(Z)-(2-phenyl-2-(quinolin-1-ium-1-yl)vinyl)(phenylsulfonyl)amide (1v):





(E)-4-methyl-N-phenyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3aa):





(E)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-*N*-(*p*-tolyl)benzenesulfonamide (3ab):





(*E*)-N-(4-methoxyphenyl)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ac):





(E)-N-(4-bromophenyl)-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ad):





(*E*)-*N*-(3-fluorophenyl)-4-methyl-*N*-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)benzenesulfonamide (3ae):





(E)-N-benzyl-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3af):





(E)-N-butyl-4-methyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3ag):





(E)-2-nitro-N-phenyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3ah):





(E)-N-phenyl-N-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)methanesulfonamide (3ai):





(E)-3-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)oxazolidin-2-one (3aj):





(E)-1-((1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*a*H)-ylidene)methyl)pyrrolidin-2-one (3ak):





(E)-4-methyl-N-((9-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ba):





(E)-N-((9-methoxy-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ca):





(E)-methyl 5-((4-methyl-N-phenylphenylsulfonamido)methylene)-1-phenyl-3-tosyl-3,4,5,5a-tetrahydro-[1,4]diazepino[1,7-a]quinoline-9-carboxylate (3da):





(E)-N-((9-bromo-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ea):





(E)-N-((9-chloro-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3fa):





(E)-4-methyl-N-((10-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ga):





(E)-N-((8-bromo-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ha):





ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3ia):



(E)-N-((1,6-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ja, *E*-isomer):





(Z)-N-((1,6-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ja, Z-isomer):





(E)-4-methyl-N-((6-methyl-1-phenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ka):





(E)-4-methyl-N-phenyl-N-((1-(p-tolyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3la):





(E)-N-((1-(4-bromophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3ma):





(E)-N-((1-(3-fluorophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3na):





(E)-N-((1-(3-fluorophenyl)-9-methoxy-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3oa):





(E)-4-methyl-N-phenyl-N-((3-tosyl-1-(3-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7- α]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3pa):





(E)-4-methyl-N-phenyl-N-((3-tosyl-1-(4-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7- α]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3qa):





(E)-4-methyl-N-((10-methyl-3-tosyl-1-(4-(trifluoromethyl)phenyl)-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-N-phenylbenzenesulfonamide (3ra):





(E)-N-((1-(3,5-difluorophenyl)-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (3sa):





5(5a*H*)-ylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (3ta):





(E)-4-methyl-N-phenyl-N-((1-phenyl-3-((4-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3ua):





(E)-4-methyl-N-phenyl-N-((1-phenyl-3-(phenylsulfonyl)-3,4-dihydro-[1,4]diazepino[1,7-a]quinolin-5(5aH)-ylidene)methyl)benzenesulfonamide (3va):



(E)-4-methyl-N-phenyl-N-((1-phenyl-3-tosyl-3,4,6,7-tetrahydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*a*H)-ylidene)methyl)benzenesulfonamide (4aa):



(E)-N-((1,9-diphenyl-3-tosyl-3,4-dihydro-[1,4]diazepino[1,7-*a*]quinolin-5(5*aH*)-ylidene)methyl)-4-methyl-N-phenylbenzenesulfonamide (5ea):



VII. Stereochemistry assignment:

First, the labelled protons and carbons in following structures of compounds **3aa**, **3aj** and **3ka** have been assigned from ^1H NMR, ^{13}C NMR in combination with 2D NMR (HSQC-GP and HMBC-GP) analysis (Figure S1).




Figure S1: Assignment of relevant protons by 2D NMR studies

Significant nOe has observed between H^e and H^g protons in compound **3aj** which confirms its *E*-stereochemistry (Figure S2). Only one case we have isolated both the isomers (*E*- and *Z*-isomers of **3ja**). Comparing the ^1H NMR and ^{13}C NMR of all other compounds with that of **3aj**, *E*-stereochemistry has been determined for all the compounds as nOe experiments were found insignificant due to presence of overlapping aromatic protons.





Figure S2: Significant nOe between H^e and H^g proton of compound **3aj**

NOE of **3aj** (irradiation of up-fielded H⁹-proton):



NOE of **3aj** (irradiation of down-fielded H⁹-proton):

